Bradycardia during therapy for multiple myeloma with thalidomide
- 1 April 2004
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (8) , 1052-1055
- https://doi.org/10.1016/j.amjcard.2003.12.061
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapyBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide and Thalidomide Analogs Reduce HIV Type 1 Replication in Human Macrophagesin VitroAIDS Research and Human Retroviruses, 1997
- Regression of AIDS-Related Kaposi's Sarcoma During Therapy with ThalidomideClinical Infectious Diseases, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Thalidomide for the Treatment of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1992
- Significant response of oral aphthosis to thalidomide treatmentJournal of the American Academy of Dermatology, 1985
- Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytesJournal of the American Academy of Dermatology, 1984
- Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosusBritish Journal of Dermatology, 1983